AR015774A1 - Derivados de epotilona 12,13-modificados y sus sales - Google Patents

Derivados de epotilona 12,13-modificados y sus sales

Info

Publication number
AR015774A1
AR015774A1 ARP990101834A ARP990101834A AR015774A1 AR 015774 A1 AR015774 A1 AR 015774A1 AR P990101834 A ARP990101834 A AR P990101834A AR P990101834 A ARP990101834 A AR P990101834A AR 015774 A1 AR015774 A1 AR 015774A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
group
aryl
heterocycle
Prior art date
Application number
ARP990101834A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR015774A1 publication Critical patent/AR015774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se trata de derivados de epotilona modificados en la posicion 12.13. de formulas: (I) y (II); Q se elige entre los grupos (1); O es alquilo, alquilosustituido, arilo, arilo sustituido, heterociclo, del grupo (2) y L representa O, S, SO2 o NR13 o CR14R15; W es O, o NR16; X es O. S, CHR17 o H2R18; A es O;S; H R19 o R20, o R21; Y se elige entre O; H, H; H,OR22; OR23;OR23,NOR24; H, NOR25; H,NR26R27; NHNR28R29; H, NHNR30R31; O CHR32; en donde OR23, OR23 puedenformar un cetal cíclico; B1 y B2 es H o un grupo OR23, OCOR34, OCONR35R36, NR37R38 O NR39CONR40R41; D es un grupo de NR42R43 o heterociclo; y los demás sesleccionan a partir de carbono, R1, R2, R3 y R4 se seleccionan a partir de H, alquilo inferior; R5, R8, R9, R10 y R11 se seleccionan a partir del grupo queconsiste de H, alquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, heterociclo o heterociclo sustituido; R6 y R7 se seleccionan del grupo queconsiste de H, alquilo, halogeno, nitro ciano, OR47, NR48R49, R50C=O, R17,R18, R22 y R23 se seleccionan a partir del grupo que consiste de H, alquilo yalquilo sustituido; arilo, acilo o arilo sustituido. R20, R21, R24, R25, R26, R28, R30, R32, R33, R34, R35, R36, R37, R39, R40, R41, R42, R47, R48, R50, R51,R52, R53, R54, R56,, R57, R58, R59, y R61 se seleccionan a partir del grupo de H, alquilo, alquilo sustituido, arilo, o arilo sustituido; R12, R13, R16, R27,R31, R38, R43, R44,, R49, R55 y R60 se seleccionan a partir del grupo que consiste en H, alquilo, alquilo sustituido, arilo sustituido, cicloalquilo,heterociclo, R51C=O,R53SO2, hidroxi, O-alquilo o alquilo O sustituido; en donde X es O entonces R16 no es R51C=O, R52OC=O, y R53SO2; y en el cual R44 es ademásamino y formula (B); R14 y R15 se seleccionan a partir del grupo que consiste en H; halogeno, alquilo o alquilo sustituido; R19 se selecciona a partir delgrupo que consiste de H, alquilo, alquilo sustituido, O-alquilo, alquilo O-sustituido, NR54R55, R56C=O; cuando L es O,S, o NR3 entonces R19 no esO-alquilo,
ARP990101834A 1998-04-21 1999-04-21 Derivados de epotilona 12,13-modificados y sus sales AR015774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8256498P 1998-04-21 1998-04-21

Publications (1)

Publication Number Publication Date
AR015774A1 true AR015774A1 (es) 2001-05-16

Family

ID=22171978

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101833A AR015007A1 (es) 1998-04-21 1999-04-21 Compuestos de 12,13-ciclopropano epotilona y sales, solvatos e hidratos de los mismos
ARP990101834A AR015774A1 (es) 1998-04-21 1999-04-21 Derivados de epotilona 12,13-modificados y sus sales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990101833A AR015007A1 (es) 1998-04-21 1999-04-21 Compuestos de 12,13-ciclopropano epotilona y sales, solvatos e hidratos de los mismos

Country Status (17)

Country Link
US (2) US6399638B1 (es)
EP (3) EP1073648B1 (es)
JP (2) JP4476483B2 (es)
CN (1) CN1142923C (es)
AR (2) AR015007A1 (es)
AT (2) ATE435861T1 (es)
AU (2) AU748526B2 (es)
BR (1) BR9909795A (es)
CA (2) CA2323609A1 (es)
CY (2) CY1105836T1 (es)
DE (2) DE69933287T2 (es)
DK (3) DK1073647T3 (es)
ES (3) ES2273484T3 (es)
PE (1) PE20000460A1 (es)
PT (3) PT1589017E (es)
TR (1) TR200003036T2 (es)
WO (2) WO1999054318A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
KR20010086073A (ko) * 1998-12-02 2001-09-07 데이비드 존 우드 ｐ53계 단백질의 배좌 안정성을 회복하기 위한 방법 및조성물
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
HUP0200583A3 (en) * 1999-03-29 2004-07-28 Bristol Myers Squibb Co A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
WO2002030356A2 (en) 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HUP0302567A2 (hu) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
EP1938821B1 (en) * 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
WO2002066033A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
ES2384789T3 (es) * 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
ES2315399T3 (es) * 2001-08-23 2009-04-01 Novartis Ag Analogos de epotilona ciclobutilo y ciclopropilo.
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003243561A1 (en) * 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2494536C (en) * 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
AU2003266961A1 (en) * 2002-08-02 2004-02-25 Novartis Ag Epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1759115A (zh) * 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101406635B1 (ko) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의 ｘ-선 결정 구조
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
WO2004032923A1 (en) * 2002-10-11 2004-04-22 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
MXPA06003835A (es) * 2003-10-09 2006-06-14 Kosan Biosciences Inc Formulaciones terapeuticas.
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
PE20061058A1 (es) * 2004-11-18 2006-10-13 Bristol Myers Squibb Co Composicion farmaceutica que comprende ixabepilona y proceso de preparacion
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc IAP BIR DOMAIN BINDING COMPOUNDS
AR061181A1 (es) * 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
EP2089411A4 (en) 2006-12-04 2010-01-27 Univ Illinois COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA
WO2008098216A2 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP2152717A1 (en) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2009146152A2 (en) * 2008-04-04 2009-12-03 Emory University Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment
MX2010011209A (es) * 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
JP2018534283A (ja) * 2015-10-16 2018-11-22 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ エポシロン類似体、合成方法、処置方法、およびその薬物結合体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
EP1201666A3 (de) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte Epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU8542898A (en) 1997-07-16 1999-02-10 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
JP4644364B2 (ja) 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
EA009206B1 (ru) 1999-02-18 2007-12-28 Шеринг Акциенгезельшафт Производные 16-галогенэпотилона и их фармацевтическое использование
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion

Also Published As

Publication number Publication date
AU757733B2 (en) 2003-03-06
EP1073647A1 (en) 2001-02-07
BR9909795A (pt) 2000-12-26
EP1073647B1 (en) 2009-07-08
CY1105836T1 (el) 2011-02-02
CN1142923C (zh) 2004-03-24
DK1589017T3 (da) 2013-03-18
ES2400049T3 (es) 2013-04-05
ATE340177T1 (de) 2006-10-15
DK1073647T3 (da) 2009-11-09
PT1589017E (pt) 2013-03-04
CA2329181A1 (en) 1999-10-28
CY1109593T1 (el) 2014-08-13
DE69933287T2 (de) 2007-05-03
PT1073647E (pt) 2009-07-17
EP1073647A4 (en) 2003-01-02
JP2002512239A (ja) 2002-04-23
AU3382799A (en) 1999-11-08
EP1073648B1 (en) 2006-09-20
EP1589017B1 (en) 2012-12-05
DE69941083D1 (en) 2009-08-20
WO1999054318A1 (en) 1999-10-28
PT1073648E (pt) 2006-12-29
PE20000460A1 (es) 2000-06-09
JP4476483B2 (ja) 2010-06-09
EP1073648A4 (en) 2003-01-02
DK1073648T3 (da) 2007-01-08
US6399638B1 (en) 2002-06-04
DE69933287D1 (de) 2006-11-02
TR200003036T2 (tr) 2001-01-22
WO1999054319A1 (en) 1999-10-28
CA2329181C (en) 2011-02-22
JP2002512238A (ja) 2002-04-23
ATE435861T1 (de) 2009-07-15
AU3471699A (en) 1999-11-08
ES2273484T3 (es) 2007-05-01
EP1589017A3 (en) 2009-04-22
AR015007A1 (es) 2001-04-11
US6380395B1 (en) 2002-04-30
CA2323609A1 (en) 1999-10-28
AU748526B2 (en) 2002-06-06
EP1073648A1 (en) 2001-02-07
EP1589017A2 (en) 2005-10-26
ES2327803T3 (es) 2009-11-03
CN1298398A (zh) 2001-06-06

Similar Documents

Publication Publication Date Title
AR015774A1 (es) Derivados de epotilona 12,13-modificados y sus sales
AR055830A1 (es) Inhibidores de cxcr2
AR016304A1 (es) Compuestos inhibidores de la farnesil proteina transferasa y las composiciones farmaceuticas que los contienen.
AR036027A2 (es) Un compuesto heterociclico substituido, procedimiento y compuestos intermediarios para su preparacion y composicion farmaceutica que contiene a dicho compuesto
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
LU93229I2 (fr) "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
CO5150230A1 (es) Derivados de azetidina, su preparacion y los medicamentos que los contienen
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
NO20023997L (no) 2-okso-1-pyrrolidinderivater, fremgangsmåter for deres fremstilling, og deres anvendelse
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
CA2124206A1 (en) Indole derivatives
AR037881A1 (es) Uso de derivados de oxindol
AR051393A1 (es) Adeninas sustituidas y sus usos
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
BR0214177A (pt) Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1
AR015434A1 (es) Derivados de eritromicina con puente en 6,9, procedimientos para su preparacion, composicion farmaceutica para tratar infecciones bacterianas que los contiene y su uso para la manufactura de un medicamento
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
TR200000414T2 (tr) 2-(4-Aril ya da heteroaril-piperazin-1-ilmetil)-1H-indol türevleri.
DK229187A (da) 1-substituerede imidazolderivater, 2-thion-tautomere og ikke-toksiske, farmaceutisk acceptable salte deraf
NO975681L (no) Benzisoxazol- og indazol-derivater som antipsykotiske midler

Legal Events

Date Code Title Description
FB Suspension of granting procedure